On November 12, the International Association for the Study of Lung Cancer (IASLC) issued a policy statement that strongly discourages the use of electronic cigarettes (e-cigarettes, or e-cigs) by non-smokers. The timing of the release is [more]
No more colorectal or lung cancer in phase 1 trials. Stretching the point, this could be the scenario in the near future following the trends described in an abstract presented at the International Congress on [more]
“Tobacco control efforts implemented since the 1960s will continue to reduce lung cancer rates well into the next half-century. Additional prevention and cessation efforts will be required to sustain and expand these gains to further [more]
To treat or not to treat? Different people respond in different ways to learning they have lesions that may or may not develop into threatening cancers. Charlotte Huff talks to ‘patients’, doctors and psychologists about [more]
Lung cancer kills more people in Europe than any other type of cancer, yet efforts to monitor and improve standards of treatment and care have lagged behind those of less fatal cancers, such as breast [more]
The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, [more]
Building a lung cancer team that works seamlessly to do the best for each patient was the biggest challenge in Enriqueta Felips career. Her focus today is on increasing collaboration across Europe, which she sees [more]
The potential for personalising lung cancer therapies is expanding rapidly. The challenge now is how to turn that potential into reality as fast as possible so patients can reap the benefits. A network of cancer [more]
Mediastinal staging of patients with lung cancer is used to avoid futile thoracotomies. Endoscopic, oesophageal and bronchial ultrasound procedures are methods to identify involved lymph nodes. The ASTER study indicates that the sensitivity of these [more]
The ZODIAC trial reported that the addition of vandetanib to docetaxel in second-line treatment of unselected patients with metastatic non-small-cell lung cancer resulted in a statistically significant improvement in progression-free survival compared with docetaxel alone. [more]